Deloitte February 21, 2019
Each year during the second week of January, health care executives from around the globe descend on San Francisco to discuss ground-breaking innovations, investment opportunities, and potential disruptive plays across the life sciences sector. During this year’s J.P. Morgan Healthcare Conference, we hosted a number of sessions with clients. A few topics—continued investment in oncology and gene therapies, more divestitures to free up cash flows, and the rapid proliferation of digital health—dominated our conversations with investors and executives from life sciences companies. There appears to be a strong demand to learn more about each of those topics. Here’s an overview of what we heard:
Three deal archetypes could drive M&A in 2019
We expect many life sciences companies will explore...
Today's Sponsors
Today's Sponsor